|
|
Olanib 150 mg is a targeted therapy medication primarily used in the treatment of certain types of cancer, notably ovarian cancer. Its active ingredient, olaparib, functions as a PARP (poly [ADP-ribose] polymerase) inhibitor, interfering with cancer cell DNA repair mechanisms, thereby inhibiting tumor growth.
Success Rate of Olanib 150 mg
The efficacy of Olanib 150 mg has been demonstrated in various clinical trials, particularly for patients with BRCA-mutated ovarian cancer. In these studies, olaparib has shown a significant improvement in progression-free survival (PFS) compared to placebo. For instance, maintenance therapy with olaparib has extended PFS by several months in patients with recurrent ovarian cancer who responded to platinum-based chemotherapy.
It's important to note that individual responses to Olanib 150 mg (Olaparib) can vary based on factors such as genetic mutations, cancer stage, and overall health. Therefore, while clinical trials provide general success rates, personal outcomes may differ.
Indications
Olanib 150 mg is indicated for:
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Dosage and Administration
The recommended dose of Olanib is 300 mg taken orally twice daily, equivalent to two 150 mg tablets per dose, for a total daily dose of 600 mg. Patients should continue treatment until disease progression or unacceptable toxicity occurs.
Olanib can be taken with or without food. Tablets should be swallowed whole and not chewed, crushed, or split. If a dose is missed, patients should take their next dose at the scheduled time without doubling up.
Contraindications
Olanib is contraindicated in patients with:
Known hypersensitivity to olaparib or any of its excipients.
Pregnancy, due to potential harm to the fetus.
Warnings and Precautions
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Cases of MDS/AML have been reported in patients receiving olaparib. Hematological toxicity monitoring is recommended at baseline and monthly thereafter.
Pneumonitis: Reports of pneumonitis, including fatal cases, have occurred. Patients presenting with respiratory symptoms should be evaluated promptly.
Embryo-Fetal Toxicity: Olanib can cause fetal harm when administered to pregnant women. Effective contraception should be used during treatment and for at least six months after the last dose.
Adverse Reactions
Common adverse reactions (≥10% of patients) include:
Nausea
Fatigue
Vomiting
Anemia
Diarrhea
Dysgeusia (altered taste)
Decreased appetite
Abdominal pain
Headache
Constipation
Serious adverse reactions include MDS/AML and pneumonitis.
Drug Interactions
Strong or Moderate CYP3A Inhibitors: Concomitant use can increase olaparib plasma concentrations. Dose adjustments may be necessary.
Strong or Moderate CYP3A Inducers: Concomitant use can decrease olaparib plasma concentrations, potentially reducing efficacy. Avoid co-administration.
Use in Specific Populations
Pregnancy: Olanib can cause fetal harm. Pregnant women should be advised of the potential risk to the fetus.
Lactation: Breastfeeding is not recommended during treatment and for one month after the final dose.
Hepatic Impairment: No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The effect of severe hepatic impairment on olaparib exposure has not been studied.
Renal Impairment: No dose adjustment is necessary for patients with mild renal impairment. For moderate renal impairment, the recommended dose is 200 mg twice daily. Olanib is not recommended for patients with severe renal impairment or end-stage renal disease.
Storage and Handling
Store Olanib tablets at room temperature, between 20°C to 25°C (68°F to 77°F). Keep the medication in its original container to protect from moisture and light. Keep out of reach of children.
Patient Counseling Information
Adherence: Emphasize the importance of taking Olanib exactly as prescribed and not to discontinue therapy without consulting their healthcare provider.
Adverse Reactions: Inform patients about the potential side effects and advise them to report any severe or persistent symptoms.
Reproductive Health: Advise women of childbearing potential to use effective contraception during treatment and for six months after the final dose. Men with female partners of reproductive potential should use effective contraception during treatment and for three months after the final dose.
Drug Interactions: Instruct patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements.
|
|
发新帖
